About this trial
Adhesive capsulitis ("frozen shoulder") causes significant pain and loss of shoulder mobility. Shoulder hydrodistension is an established treatment that can improve movement and reduce symptoms, but the procedure itself may be painful and difficult for some patients to tolerate.
This randomized clinical trial will evaluate whether performing a suprascapular nerve block with local anesthetic immediately before hydrodistension can reduce pain during the procedure, improve patient comfort, and potentially enhance clinical outcomes.
Participants will be randomly assigned to one of two groups:
hydrodistension alone, or
suprascapular nerve block followed by hydrodistension.
Pain, shoulder mobility, functional ability, psychological measures, and quality of life will be assessed at baseline, 1 month, and 3 months after the procedure. The study aims to determine whether adding a suprascapular nerve block provides better tolerability and improved recovery for patients with adhesive capsulitis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18 years or older
Clinical diagnosis of adhesive capsulitis of the shoulder
Persistent pain and functional limitation despite initial conservative treatment
Ability to understand study procedures
Disqualifiers
Known allergy or hypersensitivity to ropivacaine or methylprednisolone
Active infection (local or systemic)
Uncontrolled coagulopathy or ongoing therapeutic anticoagulation
Recent surgery of the affected shoulder
Trial design
Parallel
Treatments tested in this trial
Shoulder Hydrodistention
Procedure/SurgeryShoulder hydrodistension is performed using an anterior intra-articular approach. The procedure consists of an injection of 20 mL of normal saline, 4 mL of ropivacaine, and 40 mg of methylprednisolone into the glenohumeral joint, with the aim of capsular distension, pain reduction, and improvement of shoulder mobility.
suprascapular nerve block
Procedure/SurgeryThe suprascapular nerve block is performed under ultrasound guidance at the suprascapular notch using an injection of 2 mL of ropivacaine. The block is administered immediately before shoulder hydrodistension with the aim of reducing procedural pain and improving patient tolerance.
Treatment groups
Trial outcomes
Primary outcomes
Change in Shoulder Pain - Numeric Rating Scale for Pain (NRS 0-10)
Shoulder pain intensity at rest and/or with movement will be measured using the Numerical Rating
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: